Fig. 1: P300/CBP is required for CIC-DUX4 activity. | Oncogenesis

Fig. 1: P300/CBP is required for CIC-DUX4 activity.

From: Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma

Fig. 1

A Western blots for P300 and CBP in NCC-CDS-X1 cells after 96 h transfection with siRNAs for P300 and CBP. B ATP assay for cell viability of NCC-CDS-X1 at 72 and 96 h of post-transfection with P300 and/or CBP siRNA. Non-treated cells and cells transfected with non-targeting siRNA (scramble) were used as negative controls. Data are presented as mean ± SEM; *p < 0.05, ***p < 0.001 by one-way ANOVA. Results are presented as relative expression to control (n = 4). C ATP viability assay in the Kitra-SRS cell line in the same experimental conditions as explained in “B”. Data are presented as mean ± SEM; ****p < 0.0001, by two-way ANOVA. Results are presented as expression relative to control (n = 4). D RT-qPCR for P300, CBP, and CIC-DUX4 target genes in NCC-CDS-X1. Analyses were performed 48 h post-transfection with P300 and/or CBP siRNA. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA. Results are presented as expression relative to B2M (n = 3).

Back to article page